# Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Anti-TB Drugs Induced Liver Damage

> **NCT00405301** · PHASE4 · COMPLETED · sponsor: **All India Institute of Medical Sciences** · enrollment: 175 (actual)

## Conditions studied

- Drug Induced Hepatotoxicity
- Tuberculosis

## Interventions

- **DRUG:** Rifampicin(max dose 10 mg/kg/day), Isoniazide (max dose 5 mg/kg/day) and Pyrazinamide (max dose 25 mg/kg/day)

## Key facts

- **NCT ID:** NCT00405301
- **Lead sponsor:** All India Institute of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2008-06
- **Final completion:** 2008-12
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2012-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00405301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00405301, "Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Anti-TB Drugs Induced Liver Damage". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00405301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*